InNexus Biotechnology, Inc. (IXSBF)의 가격은 얼마입니까?

InNexus Biotechnology, Inc. (IXSBF)의 가격은 $0.0001입니다.

InNexus Biotechnology, Inc. (IXSBF)의 시가 총액은 무엇입니까?

InNexus Biotechnology, Inc. (IXSBF)의 시가 총액은 $12.63K입니다.

InNexus Biotechnology, Inc. (IXSBF) 영업이익률

InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.

연도	영업이익률	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

영업이익률

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	영업이익률	영업이익률 차이	국가
Royalty Pharma plc RPRX.US	67.93%	-	US
Swedish Orphan Biovitrum AB SOBI.ST	0.00%	-	SE
Ipsen S.A. IPN.PA	0.00%	-	FR
Recordati Industria Chimica e Farmaceutica S.p.A. REC.MI	0.00%	-	IT
Corcept Therapeutics Incorporated CORT.US	0.77%	-	US

회사

영업이익률

영업이익률 차이

국가